More Videos
SPECIAL REPORT
MOST SHARED
- Herbalife Vs. Hedge Funds
- Apple Surpasses Nokia as Top Cellphone Maker by Profits
- China Factory Output Leaps to 19-Month Highs
- Gold Heading to $1150: Art Hogan
- America Is On Sale
- Toll Brothers: More Contracts Signed, but Sales Down
- Cramer Jeers J&J, Applauds Abbott
- Adobe Cuts 680 Jobs, to Take Charge
- Should You Believe in this Rally?
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
- Retail Earnings in Focus Ahead of Shopping Season
- Apple Surpasses Nokia as Top Handset Maker by Profit
- In This Relay-Race Market, Who Gets Baton Next?
- Workers Staying Put at Their Jobs as Jobless Surges
- Three Things the US Can Do To Stop the Dollar's Decline
- Toll Brothers: More Contracts Signed, but Sales Down
- Ponzi Proceeds: Bidding on Madoff's Toys
- Bear Stearn Fund Managers Not Guilty on All Counts
- Commodity ETFs: Returns May Not Match Expectations
RSS FEED
Pharma's Market
Text Size 
 |
Not to mention the significance of an upgrade or a downgrade. But as equity research departments are being downsized or eliminated, it looks like a lot of biopharma coverage might be falling by the wayside.
The folks on Team Biopharma at Thomson Reuters keep track of analyst comings and goings. This week alone at least three firms have "dropped" coverage of the sector. Biotech analyst Jim Reddoch has left FBR and the firm suspended coverage of all but one of the companies he covered. Then this morning, in their daily sector pulse note to clients, TR says George Farmer is leaving Wachovia which is suspending coverage of the 18 biotech companies he looked after.
And also according to TR, Broadpoint Capital is "dropping coverage of the Biotechnology sector due to the departure of the covering analysts." That reportedly includes 17 ticker symbols. "Suspending", of course, is a key word, though. Certainly it's possible the firms will replace the analysts who will resume coverage. But lately, generally speaking, it seems less likely.
And that's just the tip of the iceberg. From big Wall Street firms to boutique houses, from big pharma to baby biotechs, from medical devices to healthcare services, TR points out that over the past several months there's been a flurry of analyst departures, layoffs and suspensions, drops, transitions and reviews of analyst coverage. Way too many, frankly, to list here. But not everyone's ending up on the unemployment line. TR says several former Bear Stearns analysts, for example, are popping up all over the Street.
Mark Schoenebaum, who used to be at BS, is now at Deutsche Bank. Yesterday, I listened into a pre-earnings season conference call he did for clients during which he discussed, among other things, what Amgen [AMGN
Loading...
()
]might be worth in a takeout. He estimates that if an acquirer could cut out 25 percent of costs in synergies that AMGN might be worth as much as $62 a share. "Who might buy Amgen?" Schoenebaum asked. "Give Barbara Ryan (DB's pharma analyst) a call," he said. Ryan's been saying for months that Pfizer [PFE
Loading...
()
]should buy Amgen.
DB makes a market in PFE & AMGN and owns at least one percent of the shares. It would also like to do investment banking for PFE. Pfizer Chairman and CEO Jeff Kindler and his senior management have consistently said they're not interested in doing a big deal. Meantime, PFE's market cap has fallen to number three in big pharma behind Novartis[NVS
Loading...
()
] and GlaxoSmithKline[GSK
Loading...
()
]. Johnson & Johnson's [JNJ
Loading...
()
]market cap dwarfs them all, but it's not really a drug pure-play.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes